Thermostable Vaccines Market

Thermostable Vaccines Market by Type of Molecule, Target Indications, Type of Therapy, Key Players and Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2035

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    81

  • Pages
    209

  • View Count
    10696

Thermostable Vaccines Market Overview

The thermostable vaccines market is estimated to be worth $XX  billion in 2021 and is expected to grow at compounded annual growth rate (CAGR) of 40% during the forecast period. Data presented by the WHO indicates that the current global vaccination coverage is nearly 85% this is believed to prevent close to three million deaths from diseases, such as diphtheria, tetanus, whooping cough and measles. However, it has been reported that 25% of vaccines are damaged due to cold chain malfunction (improper distribution and shipping). In some countries, about 80% of the drugs are estimated to lose their potency due to inadequate temperature control during their cold chain transportation. For some vaccines, even the slightest variations in temperature / storage conditions can adversely alter product integrity and / or viability. Over time, technological advancements in the methods of biologics development and manufacturing have prompted the developers to explore the potential of thermostable vaccines and thermostable biologics. Thermostable vaccines can be stored at room temperature for prolonged period of time, thereby eliminating the need for cold chain requirements in storage and transportation. This enables reduction in costs incurred during storage and transportation and, subsequently, the overall costs involved in mass immunization projects. In addition, it allows the suppliers to deliver the products in safe and convenient manner even to far-flung destinations.

At present, several biopharmaceutical companies and clinical research institutes are engaged in the development of thermostable vaccines and thermostable biologics, taking into consideration the rising global population, growing demand for vaccines and specific requirements of large-scale immunization initiatives. Moreover, significant efforts are being put into the development of technologies / devices, which enables transition of conventional vaccines to thermostable vaccines. The market has witnessed substantial partnership activity over the last few years. The activity in this segment of the industry has also attracted the attention of both private and public sector investors / investment funds, which have extended financial support to the initiatives of capable developer companies. Driven by the substantial progress in research in thermostable vaccines market, encouraging clinical trial results, and ongoing technological advancement, the thermostable vaccines and thermostable biologics market is anticipated to witness a commendable market growth during the forecast period.

This image highlights the context of Thermostable Vaccines and Biologics Market report. Over time, thermostable vaccines have captured the interest of medical community to provide global vaccination coverage without the requirement of cold chain transportation, thereby reducing the overall costs associated with immunization of masses This image provides list of Thermostable Vaccines and Biologics. Over 45 thermostable vaccines and biologics are being developed across different preclinical / clinical stages; a relatively higher proportion of these are designed for oral administration This image presents current market landscape of Thermostable Vaccines and Biologics. The majority of the candidates in the development pipeline are thermostable vaccines being evaluated for COVID-19 and other viral infections

Key Companies in Thermostable Vaccines Market 

Examples of key companies engaged in thermostable vaccines market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Allena Pharmaceuticals, Amarillo Biosciences, Vaxart, Tiziana Life Sciences, Diabetology (a subsidiary of Proxima Concepts), Biocon and Serum Institute of India. This market report includes an easily searchable excel database of all the companies providing thermostable vaccines and biologics, worldwide.

Recent Developments in Thermostable Vaccines Market:

Several recent developments have taken place in the field of thermostable vaccines market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In June 2023, Department of Biotechnology (DBT) received emergency use authorization  for GEMCOVAC-OM which is an omicron-specific mRNA-based thermostable booster vaccine integrated with indigenous platform technology. 
  • In April 2023, AstriVax received EUR 2.5 million grant from the Flanders Innovation & Entrepreneurship (VLAIO) agency with an aim to enhance their thermostable vaccine platform.

Scope of the Report

The "Thermostable Vaccines Market: Distribution by Type of Molecule (Vaccines and Proteins), Target Indications (Covid-19, Diabetes, Enteric Hyperoxaluria, Norovirus Infection and Rotavirus Infection), Type of Therapy, Key Players and Key Geographical Regions (North America, Europe and Asia Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2035" market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the players involved in the development of thermostable vaccines and biologics for the treatment of a variety of disease conditions. The market research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in thermostable vaccines market, across different geographies.

This image highlights competitive analysis of players engaged in the domain of Thermostable Vaccines and Biologics. In pursuit of a competitive edge, companies have undertaken several initiatives to enhance their respective offerings of thermostable products This image presents review of close to 150 peer-reviewed, scientific articles related to Thermostable Vaccines and Biologics. The rise in published scientific literature is indicative of the extensive research in this domain; research efforts are primarily focused on developing vaccines for various infectious diseases This image highlights the partnership activity undertaken by players engaged in Thermostable Vaccines and Biologics. There has been a rise in partnership activity in recent years; most of the deals were product development agreements inked for novel vaccines and biologics candidates, based in different geographical regions

Amongst other elements, the market report includes:

  • An overview of thermostable vaccines market, featuring a detailed analysis of pipeline molecules, based on several relevant parameters, such as type of molecule, type of formulation, type of manufacturing technology, trial phase (clinical, preclinical and discovery), route of administration, type of storage conditions, type of disease indication (Covid-19, diabetes and others), and target therapeutic area (infectious diseases, metabolic disorders, and others). It also includes information on the completed, ongoing and planned clinical trials for thermostable vaccines and biologics, sponsored by various industry players. It also provides insights on developer landscape along with the analysis based on several parameters, including year of establishment, company size, location of headquarters.
  • An insightful competitiveness analysis of thermostable vaccines and biologics developers, taking into consideration the supplier strength (based on expertise of the manufacturer), product portfolio strength, portfolio diversity, and number of area(s) of application.
  • A detailed analysis of close to 150 peer-review, scientific articles related to research on thermostable vaccines and biologics, such as year of publication, type of publication focus area (therapeutic area), impact factor, most popular author and most popular journals.
  • An analysis of the partnerships that have been inked by various stakeholders engaged in the development of thermostable vaccines and biologics, during the period 2015-2021, covering product development agreements, research and development agreements, licensing agreements, clinical trial agreement, licensing and manufacturing agreement, product development and commercialization manufacturing agreements, joint venture, product development and commercialization, acquisition and other types of partnership deals. 
  • An analysis of the investments made at various stages of development of the companies engaged in thermostable vaccines market, covering instances of debt financing, equity investments, Secondary offerings, seed funding, award/grant funding, post-IPO Debt, post-IPO Equity, private equity and other types of funding deals. 
  • Tabulated profiles of the key players providing thermostable vaccines and biologics. Each profile includes an overview of the company, thermostable product portfolio, recent developments, and an informed future outlook.
This image provides information on funding and investments received by players engaged in Thermostable Vaccines and Biologics. The growing interest of investors is evident from the fact that nearly USD 4 billion has been invested across more than 105+ instances, over the last seven years This image provides information on the current and future market trends and potential growth of Thermostable Vaccines and Biologics Market. Owing to the various benefits of thermostable vaccines and biologics, the market is anticipated to grow at an annualized rate of around 40% This image highlights the market segments of Thermostable Vaccines and Biologics. The overall opportunity within this market is likely to be distributed across different types of therapies, prominent players and key geographical regions

One of the key objectives of this market report is to provide a detailed market forecast analysis in order to estimate the existing market size and future opportunity of thermostable vaccines market during the forecast period. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the financial evolution of the market for the forecast period 2021-2035. For this purpose, we have segmented the future opportunity across the following market segments: Type of Molecule (Vaccines and Proteins), Target Indications (Covid-19, Diabetes, Enteric Hyperoxaluria, Norovirus Infection and Rotavirus Infection), Type of Therapy, Key Players, and Key Geographical Regions (North America, Europe and Asia Pacific and Rest of the World). To account for uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the anticipated industry’s growth.

Frequently Asked Questions

Question 1: What are thermostable vaccines?

Answer: Thermostable vaccines belong to a special class of therapeutics which can be stored at room temperature for prolonged period of time, thereby eliminating the need for cold chain requirements in storage and transportation.

Question 2: How big is the thermostable vaccines and biologics market?

Answer: The thermostable vaccines and biologics market size is estimated to be worth $XX billion in 2021.

Question 3: What is the projected market growth of the thermostable vaccines and biologics market?

Answer: The thermostable vaccines and biologics market is expected to grow at compounded annual growth rate (CAGR) of 40% during the forecast period 2021 - 2035.

Question 4: Who are the leading companies in the thermostable vaccines and biologics market?

Answer: Examples of key companies engaged in thermostable vaccines and biologics market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Allena Pharmaceuticals, Amarillo Biosciences, Vaxart, Tiziana Life Sciences, Diabetology (a subsidiary of Proxima Concepts), Biocon and Serum Institute of India.

Question 5: How many companies are currently engaged in the thermostable vaccines and biologics market?

Answer: Over 30 companies are currently engaged in the thermostable vaccines and biologics market.

Question 6: How much money has been invested in stakeholders in the thermostable vaccines and biologics market?

Answer: More than USD 3.5 billion has been invested in stakeholders engaged in the thermostable vaccines and biologics market

Question 7: How many articles related to thermostable vaccines and biologics have been published over the last few years?

Answer: Since 2016, close to 150 articles related to thermostable vaccines and biologics have been published, highlighting the increasing research activity in the industry.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com